Table 5. . Bone fractures avoided (per 1000 patients), QALYs gained and total cost per patient with weekly RIS-GR versus weekly ALN.
| Fractures avoided with weekly risedronate GR vs weekly alendronate (per 1000 patients) | |||||||
|---|---|---|---|---|---|---|---|
| Treatment duration | 1 year | 2 years | 3 years | 4 years | 5 years | Total | |
| Risedronate GR fractures | Mean | 26 | 51 | 71 | 96 | 119 | 363 |
| Minimum | 20 | 43 | 61 | 83 | 104 | 312 | |
| Maximum | 32 | 60 | 82 | 109 | 135 | 418 | |
| Alendronate fractures | Mean | 33 | 59 | 87 | 118 | 145 | 442 |
| Minimum | 26 | 51 | 76 | 104 | 129 | 387 | |
| Maximum | 40 | 69 | 99 | 131 | 161 | 500 | |
| Bone fractures avoided | Mean | -7 | -8 | -16 | -22 | -26 | -79 |
| Minimum | -6 | -7 | -15 | -21 | -25 | -75 | |
| Maximum | -8 | -9 | -17 | -23 | -26 | -82 | |
| QALYs gained per patient with weekly risedronate GR vs weekly alendronate | |||||||
|---|---|---|---|---|---|---|---|
| Treatment duration | 1 year | 2 years | 3 years | 4 years | 5 years | Total | |
| QALYs with weekly RIS-GR | Mean | 0.7679 | 0.7587 | 0.7546 | 0.7496 | 0.7445 | 3.7753 |
| Minimum | 0.6910 | 0.6833 | 0.6800 | 0.6760 | 0.6719 | 3.4022 | |
| Maximum | 0.8483 | 0.8374 | 0.8325 | 0.8263 | 0.8200 | 4.1645 | |
| QALYs with weekly ALN | Mean | 0.7669 | 0.7574 | 0.7522 | 0.7463 | 0.7406 | 3.7634 |
| Minimum | 0.6902 | 0.6823 | 0.6780 | 0.6732 | 0.6686 | 3.3924 | |
| Maximum | 0.8470 | 0.8359 | 0.8296 | 0.8225 | 0.8155 | 4.1504 | |
| QALYs gained with RIS-GR | Mean | 0.0010 | 0.0012 | 0.0024 | 0.0033 | 0.0039 | 0.0119 |
| Minimum | 0.0008 | 0.0010 | 0.0020 | 0.0028 | 0.0033 | 0.0098 | |
| Maximum | 0.0013 | 0.0015 | 0.0029 | 0.0039 | 0.0045 | 0.0140 | |
| Total cost per patient with weekly risedronate GR vs weekly alendronate | |||||||
|---|---|---|---|---|---|---|---|
| Treatment duration | 1 year | 2 years | 3 years | 4 years | 5 years | Total | |
| Risedronate GR | Mean | 281.32 € | 441.21 € | 569.19 € | 740.06 € | 909.01 € | 2940.80 € |
| Minimum | 109.76 € | 119.03 € | 129.62 € | 154.33 € | 182.47 € | 695.20 € | |
| Maximum | 627.99 € | 1064.56 € | 1407.87 € | 1849.51 € | 2282.05 € | 7231.97 € | |
| Alendronate | Mean | 834.39 € | 850.07 € | 940.77 € | 1080.22 € | 1229.98 € | 4935.43 € |
| Minimum | 597.37 € | 458.45 € | 388.72 € | 350.36 € | 337.35 € | 2132.26 € | |
| Maximum | 1282.44 € | 1582.63 € | 1964.78 € | 2428.76 € | 2878.02 € | 10,136.63 € | |
| Savings with RIS-GR | Mean | -553.07 € | -408.86 € | -371.57 € | -340.16 € | -320.97 € | -1994.63 € |
| Minimum | -487.61 € | -339.43 € | -259.10 € | -196.04 € | -154.89 € | -1437.06 € | |
| Maximum | -654.45 € | -518.07 € | -556.91 € | -579.26 € | -595.97 € | -2904.66 € | |
Bold numbers represent the final results.
ALN: Weekly Alendronate 70 mg tablets; QALYs: Quality-adjusted life-years; RIS-GR: Weekly risedronate 35 mg gastro-resistant tablets.